RUTH.AQSE

Rutherford Health Plc
Rutherford Health - Results of General Meeting
11th January 2022, 12:20
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 1024Y
Rutherford Health PLC
11 January 2022
 

Rutherford Health Plc

Results of General Meeting

 

11 January 2022: Rutherford Health plc (AQSE: RUTH, the "Company" or "Group"), a healthcare group committed to providing innovative cancer care of the highest quality, announces that at the general meeting held earlier today, all resolutions were passed with the requisite majorities.

 

The proxy results were as follows:

 

 

For

Percentage

Against

Percentage

Withheld

Resolution 1 - withdrawal from AQSE

57,672,636

84.6%

10,520,949

15.4%

109,163,381

Resolution 2 - authority to issue shares

166,836,017

94.1%

10,520,949

5.9%

0

Resolution 3 - disapplication of pre-emption rights

166,836,017

94.1%

10,520,949

5.9%

0

 

 

As a result, the last day of dealing in the Company's Ordinary Shares will be 24 January 2022 and withdrawal of the Company's Ordinary Shares from trading on AQSE will take place at 08.00 on 25 January 2022.

 

In addition, the Company is now able to issue Ordinary Shares a non pre-emptive basis up to a nominal amount of £20,136.37 (being up to 20,136,370 Ordinary Shares) and can therefore now conclude the proposed £2 million convertible loan facility with LF Equity Income Fund announced on 16 December 2021.

 

The circular dated 22 December 2021 ("the Circular"), which contains the notice convening the General Meeting, is available from the Company's website, www.rutherfordhealth.com

Any capitalised terms not defined in this announcement shall have the same meaning as those defined in the Circular.

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

For more information, please contact:

 

Rutherford Health plc

Tel: +44 (0) 16 3381 0661


Mark Jackson, Chairman

Marcus King, Finance Director

Investors@therutherford.com

 

 

Grant Thornton (Corporate Adviser)

Tel: +44 (0) 20 7383 5100

Colin Aaronson / George Grainger

 

 

 

Instinctif Partners

Tel: +44 207 457 2020

Melanie Toyne-Sewell / Jeremy Durrant / Rozi Morris /
 

Rutherford@Instinctif.com

 

 

Media House International

Tel: 07788 414 856 or 0207 710 0020

Ramsay Smith

ramsay@mediahouse.co.uk

 

 

 

About Rutherford Health plc

Rutherford Health plc is a leading UK provider of innovative cancer care. Operating a network of four state-of-the-art centres in Wales, Reading, Northumberland and Liverpool, Rutherford Health offers a comprehensive range of the latest technology in cancer treatments, and is the only independent provider of proton beam therapy ("PBT") in the UK. The Company also provides conventional radiotherapy, chemotherapy, immunotherapy, imaging and wellbeing services.

The Group is listed on the Apex segment of the AQSE Growth Market under the symbol: RUTH. For more information, visit the Group's website:  www.rutherfordhealth.com .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXFLFLFLRILLIF ]]>
TwitterFacebookLinkedIn